Adamis Prostate Cancer Drug Receives Allowance for Patent in USA

Adamis Prostate Cancer Drug Receives Allowance for Patent in USA 
SAN DIEGO, CA -- (Marketwired) -- 08/21/13 --  Adamis Pharmaceuticals
Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the
development and commercialization of specialty pharmaceutical and
biotechnology products in the therapeutic areas of respiratory
disease, allergy, oncology and immunology, today announced the
technology which constitutes its compound APC-100 received a Notice
of Allowance for its patent application in the USA. Broad claims to a
patent titled "Chroman-Derived Anti-Androgens for Treatment of
Androgen-Mediated Disorders" have been allowed. These include claims
for the use of APC-100 to reduce effects of androgens on androgen
receptor expressing cancer cells, such as prostate cancer cells.
Notice of Allowance is the final step in the issuance of a patent.
This patent will significantly strengthen Adamis' patent portfolio
for the use of APC-100 in the treatment of prostate cancer. Adamis
currently has two other small molecule drugs that are being developed
for the treatment of prostate cancer. 
APC-100 is part of a Phase 1/2a clinical study in patients with
advanced prostate cancer. Primary objectives of the trial are to
evaluate the safety and tolerability of APC-100, as well as to
determine the dose levels for subsequent trials. Secondary objectives
of the trial include pharmacokinetic analyses as well as preliminary
assessments of efficacy. To date the product has been shown to be
safe and well tolerated. Although the Phase 1 trial as originally
proposed has been substantially completed, an amendment to the IND
has been filed. This amendment provides for administering additional
higher doses to determine the maximum tolerated dose (MTD). The
ongoing trial is being conducted at the University of Wisconsin
Carbone Cancer Center and the Wayne State University Karmanos Cancer
Institute. Both of these institutions are currently named within "The
Prostate Cancer Clinical Trials Consortium."  
APC-100 has multiple modes of action. It is an orally available
anti-androgenic/anti-inflammatory, signal transduction inhibitor
drug. APC-100 has demonstrated to have higher therapeutic activity
than the current marketed Standard of Care anti-androgens.
Pre-clinical studies confi
rming the use of APC-100 for the treatment
of prostate cancer were pioneered by Dr. George Wilding and his team.
Dr. Wilding is the Assistant Dean for Oncology and Director of the
University of Wisconsin Carbone Cancer Center. In addition to
increasing time to tumor progression and survival, APC-100 also
induced a significant decrease in PSA production. These and other
characteristics make APC-100 a first-in-class compound for the
potential treatment of both castrate-sensitive and castrate-resistant
prostate cancer. 
APC-100 has previously received the National Cancer Institute's (NCI)
multi-year, multi-million dollar RAPID Award (Rapid Access to
Preventative Intervention Development). Each year, this award is
given by the NCI Division of Cancer Prevention, under the RAPID
Program (now called PREVENT), to what it believes are the most
promising new preventative/therapeutic anti-cancer drugs. 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is a biopharmaceutical company
engaged in the development and commercialization of specialty
pharmaceutical and biotechnology products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology. In addition to
the Taper technology, Adamis currently has four products in its
specialty pharmaceutical product pipeline, including the Epinephrine
Injection PFS syringe product for use in the emergency treatment of
anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and
chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled
nasal steroid product for the treatment of allergic rhinitis. The
Company's biotechnology efforts are focused on the development of
therapeutic vaccine product candidates and cancer drugs for patients
with unmet medical needs in the multi-billion dollar global cancer
markets. Its products under research and development include
TeloB-VAX, a novel cell-based therapeutic cancer vaccine and three
drugs: APC-100, APC-200, and APC-300, for the treatment of prostate
cancer. 
Forward Looking Statements 
This press release may contain forward-looking statements that relate
to future events or our future results of operations or future
financial performance, including, but not limited to the following
statements: the ability to fund future product development and
business operations; future revenues expected from any of the
company's product candidates, assuming that they are developed and
approved for marketing by the FDA and other regulatory authorities;
our ability to complete any future acquisitions of products, product
candidates or technologies; and the intellectual property protection
that may be afforded by any patents or patent applications relating
to the company's technology. Certain of these risks, uncertainties,
and other factors are described in greater detail in Adamis' filings
from time to time with the SEC, which Adamis strongly urges you to
read and consider, all of which are available free of charge on the
SEC's web site at http://www.sec.gov. Except as required by law,
Adamis expressly disclaims any obligation to update any
forward-looking statements. 
For Additional Information 
Mark Flather
Director, Investor Relations & Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com 
 
 
Press spacebar to pause and continue. Press esc to stop.